The Vision Supplement Guide: What The Shelf Rests On

Almost everything in this aisle traces back to two trials run by the National Eye Institute, and understanding them explains why the labels look the way they do.

The first, AREDS, reported in 2001. It gave participants a high-dose antioxidant formula: vitamin C 500 mg, vitamin E 400 IU, beta carotene 15 mg, and zinc 80 mg as zinc oxide WITH copper 2 mg as cupric oxide. In people with intermediate disease it reduced progression to advanced age-related macular degeneration. That result is the foundation the whole category is built on.

The second, AREDS2, reported in 2013. It asked three questions: whether adding lutein and zeaxanthin helped, whether adding omega-3 helped, and whether beta carotene could be removed and the zinc lowered. It gave lutein 10 mg and zeaxanthin 2 mg a day, for a median of five years over a median of five years.

The answers were narrower than the marketing that followed. Lutein and zeaxanthin did not significantly beat placebo in the primary analysis. Omega-3 did nothing. Removing beta carotene made no difference to the outcome and removed the lung cancer signal in smokers, which is why it was removed. And the pre-specified secondary analysis did show lutein and zeaxanthin outperforming beta carotene, which is why they are now in the formula.

the National Eye Institute’s own account of both trials is the least filtered summary available and is worth reading before any marketing page in this category.

The macula is yellow, and the yellow is lutein, zeaxanthin and meso-zeaxanthin. It can be measured in a living eye as macular pigment optical density, and that measurement is the bridge between what you swallow and anything anybody can see.

It rises with intake. It rises more in people who started low. It rises over weeks to months rather than days, which is the honest reason a supplement in this category cannot be judged in a fortnight.

The meta-analysis of pigment against visual function is the fairest summary of what raising it associates with: glare disability, photostress recovery and contrast measures move more reliably than acuity does. The one-year trial measured all three directly at lutein 10 mg and zeaxanthin 2 mg a day for one year, 115 young adults, and a 2025 trial used lutein 10 mg and zeaxanthin 2 mg twice a day for four months in adults on screens eight hours a day.

The practical translation is unglamorous and useful. This is the part of vision that decides how long you are half blind after a set of oncoming headlights, and how quickly a room resolves when you come in from bright sun. It is not the letter chart, and a category sold on sharper vision is selling the wrong thing.

The amounts are the trials', every one read out of the abstract itself. None of them is a recommendation and none is a label figure.

An eye examination finds the things that matter, and most of them are not nutritional.

A test measures pressure, looks at the optic nerve, images the retina, and checks whether the correction you are wearing is the one you now need. It finds glaucoma before it takes any field, picks up diabetic change before it is symptomatic, and catches macular change at the stage where the AREDS formula is actually indicated.

And for the single modifiable risk factor with the largest measured effect, a 2025 review of smoking and ocular health is the reference. Nothing on a supplement shelf comes close to it in either direction.

A daily capsule is a reasonable thing to add to a life that already includes those. It is a poor substitute for any of them, and the honest version of this guide has to end by saying so.